TGFBR1*6A may contribute to hereditary colorectal cancer

被引:36
作者
Bian, Y
Caldes, T
Wijnen, J
Franken, P
Vasen, H
Kaklamani, V
Nafa, K
Peterlongo, P
Ellis, N
Baron, JA
Burn, J
Moeslein, G
Morrison, PJ
Chen, Y
Ahsan, H
Watson, P
Lynch, HT
de la Chapelle, A
Fodde, R
Pasche, B
机构
[1] Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Dept Med,Div Hematol Oncol,Canc Genet Program, Chicago, IL 60611 USA
[2] Hosp Clin San Carlos, Oncol Mol Lab, Madrid, Spain
[3] Leiden Univ, Ctr Med, Ctr Human & Clin Genet, Leiden, Netherlands
[4] Erasmus Univ, Ctr Med, Dept Pathol, Rotterdam, Netherlands
[5] Columbia Univ, Mailman Sch Publ Hlth, Cell Biol Program, New York, NY USA
[6] Dartmouth Coll Sch Med, Dept Med, Hanover, NH USA
[7] Dartmouth Coll Sch Med, Dept Family & Community Med, Hanover, NH USA
[8] Inst Human Genet, Newcastle Upon Tyne, Tyne & Wear, England
[9] CAPP2 Consortium, Dusseldorf, Germany
[10] CAPP2 Consortium, Belfast, Antrim, North Ireland
[11] CAPP2 Consortium, Omaha, NE USA
[12] Ohio State Univ, Human Canc Genet Program, Columbus, OH 43210 USA
关键词
D O I
10.1200/JCO.2005.00.281
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose TGFBR1*6A is a tumor susceptibility gene that increases breast, colon, and ovarian cancer risk. Fourteen percent of the general population carries TGFBR1*6A, and TGFBR1*6A homozygotes have a greater than 10.0% increased colon cancer risk compared with noncarriers. Low-penetrance genes such as TGFBR1*6A may account for a sizable proportion of familial colorectal cancer occurrences. To test this hypothesis, we determined whether TGFBR1*6A contributes to a proportion of mismatch repair (MMR) gene mutation-negative hereditary nonpolyposis colorectal cancer (HNPCC) patients. Patients and Methods A case-case study was performed of 208 index patients with HNPCC meeting the Amsterdam criteria. Patients were examined for mutations and genomic rearrangements in the MLH1, MSH2, and MSH6 genes and genotyped for TGFBR1*6A. Tumor microsatellite instability status was available for 95 patients. Results A total of 144 patients (69.2%) carried a deleterious mutation and were classified as positive for MMR gene mutation; 64 patients (30.8%) had no evidence of mutations and were classified as MMR negative. TGFBR1*6A allelic frequency was significantly higher among MMR-negative patients (0.195) than among MMR-positive patients (0.104; P = .011). The proportion of TGFBR1*6A homozygotes was nine-fold higher among MMR-negative (6.3%) than among MMR-positive patients (0.7%; P = .032). The highest TGFBR1*6A allelic frequency was found among MMR-negative patients with tumors exhibiting no microsatellite instability (0.211), and the lowest frequency was found among MMR-positive patients with tumors exhibiting microsatellite instability (0.121); the difference was not statistically significant (P = .17). Conclusion TGFBR1*6A may be causally responsible for a proportion of HNPCC occurrences.
引用
收藏
页码:3074 / 3078
页数:5
相关论文
共 28 条
[1]  
Baxter SW, 2002, CANCER EPIDEM BIOMAR, V11, P211
[2]  
Boland CR, 1998, CANCER RES, V58, P5248
[3]  
Charbonnier F, 2002, CANCER RES, V62, P848
[4]  
Chen T, 2001, CANCER RES, V61, P4679
[5]  
Fleiss J. L., 1981, Statistical Methods for Rates and Proportions, V2nd
[6]  
Friedl W, 1999, GENE CHROMOSOME CANC, V25, P403, DOI 10.1002/(SICI)1098-2264(199908)25:4<403::AID-GCC15>3.0.CO
[7]  
2-P
[8]   DIFFERENTIAL SENSITIVITY OF SUBCLASSES OF HUMAN-COLON CARCINOMA CELL-LINES TO THE GROWTH INHIBITORY EFFECTS OF TRANSFORMING GROWTH FACTOR-BETA-1 [J].
HOOSEIN, NM ;
MCKNIGHT, MK ;
LEVINE, AE ;
MULDER, KM ;
CHILDRESS, KE ;
BRATTAIN, DE ;
BRATTAIN, MG .
EXPERIMENTAL CELL RESEARCH, 1989, 181 (02) :442-453
[9]   The prevalence of MADH4 and BMPR1A mutations in juvenile polyposis and absence of BMPR2, BMPR1B, and ACVR1 mutations [J].
Howe, JR ;
Sayed, MG ;
Ahmed, AF ;
Ringold, J ;
Larsen-Haidle, J ;
Merg, A ;
Mitros, FA ;
Vaccaro, CA ;
Petersen, GM ;
Giardiello, FM ;
Tinley, ST ;
Aaltonen, LA ;
Lynch, HT .
JOURNAL OF MEDICAL GENETICS, 2004, 41 (07) :484-491
[10]   Mutations in the SMAD4/DPC4 gene in juvenile polyposis [J].
Howe, JR ;
Roth, S ;
Ringold, JC ;
Summers, RW ;
Järvinen, HJ ;
Sistonen, P ;
Tomlinson, IPM ;
Houlston, RS ;
Bevan, S ;
Mitros, FA ;
Stone, EM ;
Aaltonen, LA .
SCIENCE, 1998, 280 (5366) :1086-1088